10 Medicare Drug Prices Drop in 2026: Complete Savings Guide

The 10 Drugs with Negotiated Prices

Here's the complete breakdown of savings for each drug (prices shown for a 30-day supply):

• Eliquis (Apixaban)
  Blood thinner | Bristol Myers Squibb & Pfizer
  Was: $521 Now: $231 56% savings
• Xarelto (Rivaroxaban)
  Blood thinner | Johnson & Johnson
  Was: $517 Now: $197 62% savings
• Januvia (Sitagliptin)
  Type 2 Diabetes | Merck
  Was: $527 Now: $113 79% savings
• Jardiance (Empagliflozin)
  Type 2 Diabetes | Boehringer Ingelheim & Eli Lilly
  Was: $573 Now: $197 66% savings
• Farxiga (Dapagliflozin)
  Diabetes, Heart Failure, Chronic Kidney Disease | AstraZeneca
  Was: $556 Now: $178 68% savings
• Entresto (Sacubitril/Valsartan)
  Heart Failure | Novartis
  Was: $628 Now: $295 53% savings
• Enbrel (Etanercept)
  Rheumatoid Arthritis, Psoriasis | Amgen
  Was: $7,106 Now: $2,355 67% savings
• Imbruvica (Ibrutinib)
  Blood Cancers | AbbVie & Johnson & Johnson
  Was: $14,934 Now: $9,319 38% savings
• Stelara (Ustekinumab)
  Psoriasis, Crohn's Disease | Johnson & Johnson
  Was: $13,836 Now: $4,695 66% savings
• NovoLog/Fiasp (Insulin Aspart)
  Type 1 & Type 2 Diabetes | Novo Nordisk
  Was: $495 Now: $119 76% savings

Who Benefits from These Savings?

In 2023, about 8.8 million Medicare Part D enrollees (out of 54 million total) filled prescriptions for these 10 drugs to treat conditions including:

• Cardiovascular disease
• Type 1 and Type 2 diabetes
• Autoimmune diseases
• Cancer
• Heart failure
• Chronic kidney disease

These medications accounted for about 20% of total Part D prescription drug spending in 2023.

How the Negotiations Worked

The Inflation Reduction Act of 2022 gave Medicare the power to negotiate drug prices for the first time. Here's how CMS approached the process:

CMS considered multiple factors during negotiations, including:

• Research and development costs
• Manufacturing and distribution expenses
• Available therapeutic alternatives
• Comparative effectiveness
• Unmet medical needs
• Patient and clinician input

What Happens Next?

The drug price negotiation program continues to expand:

• 2027: Negotiated prices for 15 additional drugs
• 2028: Another 15 drugs, including the first Medicare Part B drugs
• 2029 and beyond: 20 additional drugs negotiated each year

Current negotiated prices will be adjusted annually based on the Consumer Price Index (CPI-U).

How to Access These Savings

All Medicare Part D plans (including standalone plans and Medicare Advantage prescription drug plans) are required to:

• Include these 10 drugs on their formularies
• Make the negotiated prices available at the pharmacy counter
• Ensure mail-order and specialty pharmacies honor the new prices

No action needed on your part — the savings apply automatically when you fill your prescription.

Important Notes

• Timing: Prices effective since January 1, 2026
• Additional savings: These negotiated prices work alongside the $2,000 annual out-of-pocket cap for Part D that began in 2025
• Plan requirements: All Part D plans must cover these drugs at the negotiated prices
• Annual adjustments: Prices may increase modestly each year based on CPI

Questions About Your Drug Costs?

If you're currently taking one of these medications and haven't seen the savings at your pharmacy:

• Contact your Part D plan's customer service
• Verify your pharmacy has the updated pricing
• Ask about additional manufacturer discounts or copay assistance programs